{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:08:27Z","timestamp":1761487707753},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,10,27]],"date-time":"2006-10-27T00:00:00Z","timestamp":1161907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s00277-006-0207-0","type":"journal-article","created":{"date-parts":[[2006,10,26]],"date-time":"2006-10-26T07:42:03Z","timestamp":1161848523000},"page":"81-87","source":"Crossref","is-referenced-by-count":28,"title":["Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma\u2014role of radioimmunotherapy"],"prefix":"10.1007","volume":"86","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"von Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Freund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,27]]},"reference":[{"key":"207_CR1","doi-asserted-by":"crossref","unstructured":"Winter J (2004) Low-grade lymphoma. Hematology: American Society of Hematology, Educational Program Book, pp 208\u2013212","DOI":"10.1182\/asheducation-2004.1.203"},{"key":"207_CR2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med 311:1471\u20131475","journal-title":"N Engl J Med"},{"issue":"2","key":"207_CR3","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC et al (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25(2):11\u201316","journal-title":"Semin Hematol"},{"issue":"Suppl 1","key":"207_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/11.suppl_1.S23","volume":"11","author":"SJ Horning","year":"2000","unstructured":"Horning SJ (2000) Follicular lymphoma: have we made any progress? Ann Oncol 11(Suppl 1):23\u201327","journal-title":"Ann Oncol"},{"key":"207_CR5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P et al (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15:1110\u20131117","journal-title":"J Clin Oncol"},{"key":"207_CR6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 362:516\u2013522","journal-title":"Lancet"},{"issue":"13","key":"207_CR7","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","volume":"100","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM et al (2002) Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351\u20134357","journal-title":"Blood"},{"key":"207_CR8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"AZS Rohatiner","year":"2005","unstructured":"Rohatiner AZS et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215\u20132223","journal-title":"J Clin Oncol"},{"issue":"21","key":"207_CR9","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918\u20133927","journal-title":"J Clin Oncol"},{"key":"207_CR10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667\u20132674","journal-title":"Blood"},{"key":"207_CR11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P Laughlin Mc","year":"1998","unstructured":"Mc Laughlin P et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"issue":"12","key":"207_CR12","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly x 4 schedule. Blood 103(12):4416\u20134423","journal-title":"Blood"},{"key":"207_CR13","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W et al (2005) Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"207_CR14","doi-asserted-by":"crossref","unstructured":"Herold M et al (2004) Results of a prospective open-label phase III-trial: R-MCP vs. MCP alone in untreated advanced indolent lymphoma and MCL. Blood 104 (Suppl. 11):169a (abstract # 584)","DOI":"10.1182\/blood.V104.11.584.584"},{"issue":"4","key":"207_CR15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417\u20131423","journal-title":"Blood"},{"key":"207_CR16","doi-asserted-by":"crossref","first-page":"567s","DOI":"10.1200\/jco.2005.23.16_suppl.567","volume":"23","author":"MH Dreyling","year":"2005","unstructured":"Dreyling MH et al (2005) Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23:567s (abstract #6528)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR17","doi-asserted-by":"crossref","unstructured":"Hiddemann W et al (2005) Rituximab maintenance following a Rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 106(11):270a (abstract #920)","DOI":"10.1182\/blood.V106.11.920.920"},{"key":"207_CR18","unstructured":"Radioimmuntherapie mit [90Y]-Ibritumomab-Tiuxetan [90Y]-Zevalin\u00ae. Empfehlung der Strahlenschutzkommission. 198. Sitzung am 17.02.2005"},{"key":"207_CR19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE et al (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 21:1263\u20131270","journal-title":"J Clin Oncol"},{"issue":"10","key":"207_CR20","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20(10):2453\u20132463","journal-title":"J Clin Oncol"},{"issue":"2","key":"207_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","volume":"5","author":"LI Gordon","year":"2004","unstructured":"Gordon LI et al (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5(2):98\u2013101","journal-title":"Clin Lymphoma"},{"key":"207_CR22","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI et al (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase I\/II-study. Blood 103:4429\u20134431","journal-title":"Blood"},{"issue":"4","key":"207_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C Emmanouilides","year":"2006","unstructured":"Emmanouilides C et al (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 47(4):629\u2013636","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"207_CR24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/cbr.2004.19.478","volume":"19","author":"RJ Schilder","year":"2004","unstructured":"Schilder RJ et al (2004) Follow-up results of a phase II-study of ibritumomab radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 19(4):478\u2013481","journal-title":"Cancer Biother Radiopharm"},{"key":"207_CR25","doi-asserted-by":"crossref","first-page":"575s","DOI":"10.1200\/jco.2005.23.16_suppl.575","volume":"23","author":"RJ Schilder","year":"2005","unstructured":"Schilder RJ et al (2005) Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL. Proc Am Soc Clin Oncol 23:575s (abstract #6562)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR26","doi-asserted-by":"crossref","first-page":"575s","DOI":"10.1200\/jco.2005.23.16_suppl.575","volume":"23","author":"SA Gregory","year":"2005","unstructured":"Gregory SA et al (2005) Superior outcomes associated with earlier use: experience with tositumomab and iodine 131I tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin\u2019s lymphoma (NHL). Proc Am Soc Clin Oncol 23:575s (abstract #6561)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441\u2013449","journal-title":"N Engl J Med"},{"issue":"11","key":"207_CR28","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V104.11.2633.2633","volume":"104","author":"JW Sweetenham","year":"2004","unstructured":"Sweetenham JW et al (2004) Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 104(11):720a (abstract #2632)","journal-title":"Blood"},{"issue":"4","key":"207_CR29","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning SJ et al (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23(4):712\u2013719","journal-title":"J Clin Oncol"},{"key":"207_CR30","first-page":"266a","volume":"21","author":"MS Czuczman","year":"2002","unstructured":"Czuczman MS et al (2002) Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin\u2019s lymphoma. Proc Am Soc Clin Oncol 21:266a (abstract #1062)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR31","doi-asserted-by":"crossref","first-page":"575s","DOI":"10.1200\/jco.2005.23.16_suppl.575","volume":"23","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS et al (2005) Tositumomab and iodine 131I tositumomab: efficacy and safety in 141 patients with previously untreated low-grade non-Hodgkin\u2019s lymphoma (NHL). Proc Am Soc Clin Oncol 23:575s (abstract #6560)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"5","key":"207_CR32","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","volume":"102","author":"OW Press","year":"2003","unstructured":"Press OW et al (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102(5):1606\u20131612","journal-title":"Blood"},{"key":"207_CR33","first-page":"560","volume":"23","author":"DL Shipley","year":"2004","unstructured":"Shipley DL et al (2004) Phase II trial of Rituximab and short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 23:560 (abstract #6519)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR34","doi-asserted-by":"crossref","first-page":"579s","DOI":"10.1200\/jco.2005.23.16_suppl.579","volume":"23","author":"DL Shipley","year":"2005","unstructured":"Shipley DL et al (2005) Rituximab with short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 23:579s (abstrac #6577)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2","key":"207_CR35","first-page":"S7","volume":"5","author":"R Schilder","year":"2004","unstructured":"Schilder R et al (2004) Subsequent therapy for non-Hodgkin\u2019s Lymphoma is feasible after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin\u00ae). Hem J 5(Suppl 2):S7 (abstract #019)","journal-title":"Hem J"},{"issue":"3","key":"207_CR36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","volume":"5","author":"SM Ansell","year":"2004","unstructured":"Ansell SM et al (2004) Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive Non-Hodgkin\u2019s lymphoma: a review of the literature. Clin Lymphoma 5(3):202\u2013204","journal-title":"Clin Lymphoma"},{"key":"207_CR37","first-page":"232b","volume":"20","author":"L Gordon","year":"2001","unstructured":"Gordon L et al (2001) High-dose therapy can be safely and successfully administered after Zevalin\u00ae treatment. Proc Am Soc Clin Oncol 20:232b (abstract #2681)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR38","first-page":"2896","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A et al (2005) A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. J Clin Oncol 106:2896\u20132902","journal-title":"J Clin Oncol"},{"key":"207_CR39","unstructured":"Winter J et al (2004) Zevalin\u00ae dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin\u2019s lymphoma. Blood 103(11):329a (abstract #1162)"},{"key":"207_CR40","doi-asserted-by":"crossref","first-page":"576s","DOI":"10.1200\/JCO.2005.01.180","volume":"23","author":"AY Krishnan","year":"2005","unstructured":"Krishnan AY et al (2005) The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma (NHL). Proc Am Soc Clin Oncol 23:576s (abstract #6566)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"207_CR41","doi-asserted-by":"crossref","unstructured":"Weigert O et al (2006) Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLSG. Proc Am Soc Clin Oncol 24:422s (abstract #7502)","DOI":"10.1200\/jco.2006.24.18_suppl.7533"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-006-0207-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0207-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T14:19:27Z","timestamp":1683641967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-006-0207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,27]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1007\/s00277-006-0207-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,27]]}}}